Risk factor
Strong & resilient to price shocks
Profitability factor
Favourable analyst view
About
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB
Target Price
The average target price of JUBLPHARMA.NS is 1415 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation
Buy
Sell